Prof. Xu is a senior group leader at the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland. His research focuses on control preparation of layered double hydroxide nanomaterials, calcium phosphate nanoparticles, nanoemulsions, quantum dots, chemosensros and nanosensors, and their applications in biomedicine and agriculture. He has published over 330 peer-reviewed journal papers, conference papers and book chapters. His research has led to many high quality papers published in Nature Plants, Adv Mater, Nano Letters, JACS, Angew Chim Int Ed, Adv Funct Mater, Biomaterials, J Control Release, Chem Mater, Small, Nanoscale, ACS Appl Mater Interface and nanomedicine. Specifically, his publications on layered double hydroxide materials from 2008-2018 rank him in the top #6 among more than 1000 scientists in this research field in terms of the journal paper count. His papers have been cited over 19,395 times with the H-index of 75. He works as Editorial Board Member for six journals, such as Journal of Nanotechnology and Smart Materials, Frontiers in Inorganic Chemistry, Biointerface Research in Applied, and Current Pharmaceutical Design. He also served as reviewers of over 20 journals, including JACS, Biomaterials, Small, Nature Commun, Nanoscale, Adv Functional Mater, Chem Mater, ACS Appl Mater Interface, J Mater Chem B, J Phys Chem B and C.

Dr. Huang focuses on the molecular mechanism of obesity (BAT development and iWAT browning), diabetes (selective and total insulin resistance) and cancer therapy. He has published more than 30 papers (first author or corresponding author) in scientific journals including Nature Communications (3 papers); Advanced Science; Cell Reports; Journal of Biological Chemistry; Developmental Cell. He was awarded Top 1% global reviewer in the field of Clinical Medicine, Molecular Biology & Genetics and Cross-field by Web of Science Group and Publons in 2018 and 2019; He served as a grant reviewer for Nature Science Foundation of China (life science and medicine); He also served as a reviewer for 50 SCI journals and a scientific editor for 10 SCI journals.

Prof. Chen has been engaged in cutting-edge nanotechnology research for many years and he is an internationally renowned expert in nanomedicine and cancer nanotechnology. He is well known for his inventions in cancer nano-targeted therapy and deep cancer photodynamic therapy. Currently he has published more than 320 papers in famous academic journals such as PNAS (IF 12.779), Nano Letters (IF 12.262), Signal Transduction and Targeted Therapy (IF 38.104), Advanced Materials (IF 32.086), Advanced Functional Materials (IF 18.808), Materials Today Physics (IF 11.02), Bioactive Materials (IF 16.874), Coordination Chemistry Reviews (IF 24.833) etc. He has 20 US patents granted and He has been funded with more 30 scientific research projects with a total funding of more than 9 million U.S. dollars. He was one of the 35 scientists from the country (US) to be included in the National Academy of Inventors 2020 class of Senior Members. He was elected be a Fellow of the International Association of Advanced Materials (IAAM) and a Vebleo Fellow in 2020, a Sigma Xi full member, a Pencis award for International Research Awards on Oncology and Cancer Research and a Fellow of Royal Society of Chemistry (UK) in 2021 and the IMMA scientist award in 2022 for his outstanding contribution to Nanotechnology. He conceived and initiated a new Homeland Security Research Center at UTA and serve as the director for this center - the Center for Security Advances Via Applied Nanotechnology (SAVANT) from 2012 to 2018.

Dr Seifedine Kadry has a bachelor’s degree in 1999 from Lebanese University, MS degree in 2002 from Reims University (France) and EPFL (Lausanne), PhD in 2007 from Blaise Pascal University (France), HDR degree in 2017 from Rouen University. He is a Professor of Data Science at Noroff University College, Norway. At present his research focuses on Data Science, education using technology, system prognostics, stochastic systems, and applied mathematics. He is an ABET program evaluator for computing, and ABET program evaluator for Engineering Tech. He is a Fellow of IET, Fellow of IETE, and Fellow of IACSIT. He is a distinguish speaker of IEEE Computer Society.

Prof. Dr. Alireza Heidari is a Full Distinguished Professor and Academic Tenure of Chemistry and also Enrico Fermi Distinguished Chair in Molecular Spectroscopy at California South University (CSU), Irvine, California, USA. He has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. He has participated at more than seven hundred reputed international conferences, seminars, webinars, around the world as yet. Also, he possesses many published articles in Web of Science, Scopus, SCIE, SSCI, AHCI, ESCI, HEC, PMDC, PubMed, Medline and NLM. His papers have been cited over 24000 times with the H-index of 97. Moreover, he has been a senior advisor in various industries and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than one thousand reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international and peer–reviewed journals, books and publishers. Hitherward, he is a member of more than seven hundred reputed international academic–scientific–research institutes around the world.

The main goals of his research projects are to understand disease pathogenesis and to find novel therapeutic targets. Dr. Sebastian won Young Investigator Award for outstanding research by a postdoctoral fellow, and British Microcirculation Society poster prize. He published research articles on Mol Ther Methods Clin Dev, Molecular Oncology, Oncogenesis, British Journal of Cancer, Am J Respir Crit Care Med and Cancer Cell. He also served as a reviewer and Editorial Board Member for many journals such as Clinical and Translational Discovery, Highlights of Molecular Science, Frontiers in Genetics, World Journal of Clinical Oncology, Frontiers in Oncology, Chemical Communications, Cancer Immunology, Clinical Cancer Research, etc.

Since August 2019, Dr. Kashyap has been an associate professor at the Stem Cell Institute, Amity Medical School, Amity University, Haryana. He earned the PhD degree in a joint PhD program by the Johns Hopkins University School of Medicine, Baltimore-Institute of Bioinformatics, Bangalore, under the mentorship of Prof. Akhilesh Pandey, and a postdoctoral fellowship from the Moores Cancer Center, University of California, San Diego (Jan 2012-Jan 2017) in the group of Prof.(s). Januario E. Castro, and Tom Kipps. Currently, he is involved in determining the molecular mechanism of RNA splicing using splicing modulators in gastrointestinal cancers through genomics/proteomic approaches. Additionally, his group is attempting to target the receptor-ligand axis to overcome the protection of the tumor microenvironment and its relevance in GI malignancies using anti-receptor antibodies/small molecules. He has ~6000 citations with an h-index of 27. He is an associate editor of Molecular Cancer, BMC Cancer, and Frontiers in Oncology. He published papers in journal of repute like Molecular Cancer, PNAS, PLOS Medicine, Nucleic Acid Research, JACS, Journal of Hematology & Oncoogy, Angewandte Chemie, Cancer Biology & Therapy, ACS Chemical Biology, J of Medicinal Chemistry, Biomarker Research, and J Exp Clin Cancer Res.

Prof. Liu is currently the Professor and PI at State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Her research area is focused on pancreatic cancer microenvironment and chemoresistance. In recent years, Prof. Liu has published more than 20 SCI papers in high impact journals including Gastroenterology (5), Clinical Cancer Research (7), Cancer Research, Drug Resistance Updates, EbioMedicine etc and published one editorial paper in Gastroenterology. Prof. Liu received Outstanding Young Investigator Award from American Pancreatic Association (APA) and International Associate for Pancreatology (IAP) for several times. Prof. Liu is the PI of General Program supported by the National Natural Science Foundation of China. Prof. Liu is the 2nd Council of Pancreatic Association-Chinese International Exchange and Promotion Association for Medical and Health Care.

Dr. Yutong Zhao graduated from Dalian Medical University in China, and received his PhD from Gifu University School of Medicine in Japan. We conducted his postdoctoral training at the Johns Hopkins University School of Medicine. He started his independent academic career at the University of Chicago, and was promoted to Associate and full professor at the University of Pittsburgh. Currently, Dr. Zhao is a professor of Physiology and Cell Biology at the Ohio State University. His research is focused on molecular regulation of protein stability in lung diseases including lung cancer, lung injury, and pulmonary fibrosis. Dr. Zhao has published more than 125 research articles in peer-reviewed journals including Nature Communication, Molecular Cancer, and Circulation Research etc.

Dr. Huang is currently a distinguished professor at Wenzhou Medical University and a senior PI and doctoral supervisor at Oujiang Laboratory. He has won two second prizes in the Military Science and Technology Progress Award. He received the ORISE Science and Education Award in the United States in 1999 and the National Research Council Research Award in 2000; In 2011, he was appointed as an expert in the National Innovation Thousand Talents Program by the Central Organization Department. As of December 2019, he has received funding for 15 NIH research projects totaling over $25 million.  He has published over 330 SCI indexed papers in journals such as PNAS (3), Cancer Res (15), Clinical Cancer Res, Advanced Science, Autophagy (5), EHP (4), Cell Death and Differentiation (2), J Cell Biol (2) and Oncogene (15). The total citation has exceeded 25000 times, with the H-index of 68. Selected in the 2022 Global Scholar Academic Influence Ranking "Medical Field" Domestic Scholar Academic Influence Ranking and Selected in the 2022 China Clinical Medicine High Cited Scholar Ranking by Elsevier, as well as the 2023 Stanford University and Elsevier Annual Top 2% Global Scientists' Career Influence Ranking.

Dr. Jin is a Professor at Lanzhou University. He received his Ph.D. and M.D. degree at the Fourth Military Medical University followed by famous neurobiologist Prof. Gong Ju, a CAS member. At 2006, he joined the Institute of Neurosciences at Shanghai Jiao Tong University as an Associated Professor. At 2021, he was recruited to Lanzhou University. His lab is focused on molecular mechanism of axon regeneration, tumor epigenetics and cancer neuroscience. As PI, Dr. Jin was rewarded four grants from National Natural Science Foundation of China in the last five years. He has published more than 100 peer-reviewed publications and their findings have been published in some important professional journals, such as Cell, Nature Communications, Trends Pharmacol Sci, Cancer Res, Cell Death and Differentiation, Biomaterials, Pharmacology & Therapeutics, Med Res Rev, Cancer Letters, Molecular and cellular Neuroscience, J Comp Neurol and Anesthesiology.

Dr. Xufeng Chen graduated from the University of Chinese Academy of Science (Shanghai Institute of Biochemistry and Cell Biology, SIBCB), and is now working as an instructor in the New York University Grossman School of Medicine. His research area is focused on understanding the regulation of leukemogenesis and the acquisition of drug resistance in myeloid leukemias, as well as developing novel combinational therapies for circumventing drug resistance to targeted therapies and immunotherapies. In recent years, Dr. Chen has published several SCI papers in high impact journals including Cell, Cancer Discovery, Cell Research, Nature Communications, Cell Report, PNAS, Blood etc. Dr. Chen received the “Leukemia Research Foundation (LRF) Hollis Brownstein Research Grants Program” and the “American Society of Hematology (ASH) Scholar Award”.

Dr. Qiao Lu focuses on the understanding of tumor immune evasion mechanisms and to develop the next-generation immunotherapies for treating cancer. He has published high-quality papers in scientific journals including Immunity, Nature communications, Nano letters, Cell research, and so on. He also serves as reviewer for Aging, BMC Immunology, Cancer Cell International, Journal of Medical Discovery, Frontiers in Genetics, Frontiers in Immunology, Heliyon, Open Medicine, Discover Oncology, and PLOS ONE. 

Dr. Dongdong Wang is a senior scientist at McMaster University. His current research is focused on drug-discovery for cardiovascular disease, NASH, obesity, and diabetes. He has published more than 60 peer-reviewed articles in high prestigious journals such as Nature, Nature Review Endocrinology, Nature Metabolism, Pharmacological reviews, Biotechnology Advances, Seminars in Cancer Biology, and many others. He has co-edited several special issues of scientific journals. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 50 journals.

Dr. Natale Quartuccio is a consultant in Nuclear Medicine at the A Nuclear Medicine Department, A.O.O.R. Villa Sofia – Cervello, Palermo, Italy. In 2009, he graduated from the Medical School of the University of Palermo. In 2015, he completed his specialty training in Nuclear Medicine at the University of Messina and an MD (Doctor of Medicine) at the School of Health Sciences (Division of Informatics, Imaging & Data Sciences) of the University of Manchester in 2019. Dr. Quartuccio has been a visiting researcher and clinical research fellow in various national and international research institutes. In 2012 (June-November), he was a recipient of the Bradley-Alavi Student Fellowship at the Memorial Sloan Kettering Cancer Center, New York, USA and visiting student at the University of Turin (August 2013-March 2014). He was also appointed as a Clinical Research Fellow (October 2015-June 2017) at the Wolfson Molecular Imaging Centre, University of Manchester, UK and as an Honorary Clinical Fellow at the Nuclear Medicine Department of the Central Manchester University Hospitals NHS Foundation Trust (February 2016 - May 2017). His research interests include conventional nuclear medicine, applications of PET imaging to the oncological field and hypoxia imaging.

Dr. Arvind Singh Negi was Born on 1st January 1970 at Kotdwara, district Pauri Garhwal in Uttaranchal (India). He did B.Sc. in Physics, Chemistry and Mathematics from Lucknow Christian Degree College in 1989 and did M.Sc. in Organic Chemistry from University of Lucknow in 1991. After qualifying CSIR-UGC examination, he joined at Central Drug Research Institute, Lucknow, India as Junior Research Fellow in February, 1992 for Ph.D. programme. He did his doctorate on synthesis of hormone antagonists as fertility-regulating agents in 1999. In 1995, he joined Indian Grassland and Fodder Research Institute, Jhansi (IGFRI-ICAR) as Scientist and afterwards in 2000, he joined Central Institute of Medicinal and Aromatic Plants (CIMAP-CSIR), Lucknow, as Scientist ‘C’. He worked on 17 research papers and has 5 US patents in his credit. Presently, working on natural product chemistry and modification of phytomolecules to anticancer agents.

Abhimanyu Thakur obtained his B. Pharm. (2009-2013) from B.C.D.A. College of Pharmacy & Technology (affiliated to West Bengal University of Technology, Kolkata, India), and M. Pharm. (2013-2015) from the Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology (BIT) Mesra, Ranchi, India. After working in Quintiles Research Ltd. (now IQVIA) as Pharmacovigilance Safety Associate, he joined Dr. Youngjin Lee's lab at Department of Biomedical Sciences, City University of Hong Kong (CityU) in September, 2015. He obtained Ph.D. in Biomedical Sciences (Glioma Biology) in Aug 2019. His Ph.D. work is about glioma (brain cancer) biology. Currently, he is working as a Post-doctoral Fellow. Currently, he has published over 30 research papers in prestigious journals, including Bioactive Materials (IF=14.593), Science Advances (IF=14.139), Protein and Cell (IF=14.87), Chemical Engineering Journal (IF=13.237), Biosensors and Bioelectronics (IF=10.619), etc.

Dr. Jindong Chen earned his Ph.D. from Karolinska Institute, Sweden, and completed his post-doctoral work at Van Andel Research Institute. Afterwards, he worked as a Research Scientist at Van Andel Research Institute and then Senior Research Scientist at National Cancer Centre of Singapore and Duke University-NUS Graduate School. In 2012, he joined the University of Rochester Medical Center as a Research Associated Professor and become the co-director of Urological Laboratory. He is proficient at cancer biology, animal cancer modeling, and tumor metastasis. To date, Dr. Chen has published more than 110 papers and four books on cancer. Currently, he is the Chief Technology Officer at Exploring Health, LLC. and his research interest is focused on developing anti-metastatic drugs and related targeted therapy.

He is the Director of the Institute of Medical Microbiology of Fudan University, the Fellow of the American Academy of Microbiology. He has undertaken more than 30 research grants from NIH of the USA, NSFC and other foundations, with a total funding of more than 200 million yuan. He has published 561 SCI papers with 38,311 citations and an h-index of 96 (Google Scholar). Since 2020, he has published 120 SCI papers in high-profile journals, e.g., Lancet, Cell (x2), Nature, Science (x2) and their sister journals (x44), with a total impact factor of 2,600 (average per paper: 21.8). He has served as a Consultant Editor for the Lancet, Associate Editor for Viruses, and Editorial Board Member for Antiviral Res and other 9 SCI journals. He has been granted 25 U.S. patents and 26 Chinese and PCT patents, of which 11 have been successfully licensed out, and several medical products are in the market.

He is the Fellow of the American Academy of Microbiology, the Program Director of Viruses and Emerging Pathogens Program, Associate Director of OSU Infectious Diseases Institute, Center for Retrovirus Research, OSU.

Dr. Murtaza Hasan focuses on nano-biotechnology, green synthesis and cancer detection. He has won NRPU Research project with funding 2.7 million. Until now, he has published more than 110 research articles in scientific journals including Nano Research, Nano Convergence, Environmental Research, Acs Sensors, Journal of Alloys and Compounds, Materials Today Communication, Antioxidants, Journal of Materials Research and Technology, etc. And he works as guest editor for Frontier in Chemistry and Applied Science. He also served as reviewers for nearly 40 articles in prestigious journals, including International Journal of Molecular Science, Molecule, Recent Progress in Material, International Journal of Molecular Science, etc.

Ricardo Izurieta, MD, Dr.PH, MPH is Professor and Director of Global Communicable Diseases at College of Public Health and Director of the Public Health Scholar Concentration at Morsani College of Medicine, University of South Florida in Tampa. In 2003, Dr. Izurieta was elected Vice President of the Gorgas Memorial Institute of Tropical and Preventive Medicine and currently he is its Latin American Liaison. He has been Panel Reviewer for NIH, CDC, and NSF, Wellcome Foundation, and also served on the ACAIM Taskforce on International Health Security, Consultant for the United Nations Global Water Pathogens Project as well as for the United Kingdom and the Brazilian Academies of Sciences. 

Dr. Rami Ahmad El-Nabulsi focuses on general relativity and gravitation, operators theory, quantum field theory, plasma MHD and planetary dynamics, chaos and bifurcations, reactor physics and nuclear sciences, solid state physics and magnetism, quantum electronics. He has been selected as the “Top 2% Scientists“ in 2022 and 2023 respectively. Until now, he has published more than 330 articles in peer refereed journals with Impact Factor, such as Chaos, Solitons & Fractals, Nonlinear Dynamics, Applied Mathematics Letters, Journal of Physics and Chemistry of Solids, Fractals, Applied Mathematics and Computation, etc. And he works as Editorial Board Member for 25 journals. He also served as reviewers for more than 150 journals.

Dr. Zhang is an Assistant Member (equivalent to Assistant Professor) and Assistant Attending Physicist in the Department of Medical Physics at Memorial Sloan Kettering Cancer Center. His clinical responsibility is to provide broad physics services and consultation to ensure safe and accurate radiotherapy for cancer patients. His research interests include mathematical modeling of imaging systems and underlying physics; integration of sophisticated models into advanced model-based reconstruction methods; and translation of such approaches to clinical applications in both diagnostic imaging and image-guided radiation therapy. He has published more than 35 peer-review journal articles and 50 conference papers and abstracts in medical imaging. He also serves as scientific committee member for several conferences and ad hoc reviewer for 20+ journals.

Dr. Chengliang Yin is an engineer of Medical Big Data Research Center, Chinese PLA General Hospital. He is mainly engaged in the research of the medical big data area of clinical research and bioinformation, including precision medicine, prognostic model and artificial intelligence applications to data analysis. Chengliang Yin has published about 60 research papers, of which 36 articles with first or corresponding author. The main part-time jobs include specialized committee member of tumour etiology and the specialized committee on tumour markers of the Chinese anti-cancer association. Currently, he serves as an advisory board member of Heliyon, and editor for several journals. He is the reviewer for many reputed journals.

Dr. Wei Zhao is currently an associate professor at the school of Laboratory Medicine at the Chengdu Medical College. His active research fields include (1) reversal of multidrug resistance induced by reprogrammed metabolism, (2) new drug research and development for treatment of cancer patients, (3) primary cancer tissue culture and test of drug sensitivity for personalized chemotherapy. He has published over 30 papers in related fields, including Oncogene, JBC, Front. Immunol and Mol. Cancer.

Dr. Lingxiao Zhang focuses on the development of two-dimensional clay materials-based nanobiotechnological drugs and nanovaccines for the diagnosis and therapy of malignant tumors and neurodegenerative diseases. Up till now, he has published 24 high-quality articles in well-known journals such as Advanced Materials, ACS Nano, Advanced Drug Delivery Reviews, Nano Today, Biomaterials, Nano Research, ACS Applied Materials & Interfaces and Journal of Nanobiotechnology with an average impact factor of 15.272. He was also awarded with numerous honors include the TOP100 Excellent Doctoral Dissertation of the Chinese Academy of Sciences, Dean's Excellence Award of the Chinese Academy of Sciences and European Commission Horizon Seal of Excellence. As project leaders, he has undertaken a number of projects such as Chinese National Natural Science Foundation Project and HORIZON TMA MSCA Postdoctoral Fellowships with a total funding of CNY 4 million. He also serves as a Guest Editor of Journal of Nanobiotechnology, and journal reviewer for Coordination Chemistry Reviews, Acta Biomaterialia and Journal of Nanobiotechnology.

Dr. Song focuses on epigenetic mechanism underlying Western medicine and traditional Chinese medicine therapies for patients with digestive system cancers. He has published more than 30 papers in scientific journal including Signal Transduction and Targeted Therapy (IF=38.104), Clinical and Translational Medicine (IF=11.492), Pharmacological Research (IF=10.334) etc. He has leaded and contributed numerous public funded research and industry projects including National Natural Science Foundation of China and China Postdoctoral Science Foundation. He was accredited Youth Wan Jiang Scholar of Anhui Province and Excellent Young Scholars Project of Natural Science Foundation of Anhui Province in China.

Prof. Wang is currently a Professor at Xi’an Jiaotong University, and also a Fujian Provincial “Minjiang Scholar” Chair Professor. His main research area is biomedical imaging and cancer theranostics. In recent years, Prof. Wang has published more than 40 SCI papers in international mainstream journals such as PNAS, Nature Protocols, Nucleic Acids Research, Oncogene, etc. He also authorized more than 10 Chinese invention patents, and won the first prize of Shaanxi Provincial Higher Education Science and Technology Award, the third prize of the Shaanxi Provincial Science and Technology Award as the first contributor.

Pawar is an Assistant Professor (tenure-track) in Department of Computer Science and Biology at Claflin University with a Masters in Computer Science and a Ph.D. from Georgia State University, Atlanta. He’s also an co-founder of a Connecticut based AI company, ChestAi, and a research affiliate at Yale University School of Medicine. Until last year, he was an Associate Research Scientist at Yale Center for Genome Analysis. His dissertation was focused on big data (next-generation sequencing, microarrays, X-ray crystallography etc.) analysis with machine learning techniques (Neural networks, SVM’s, Restricted boltzmann machines, Clustering algorithms etc.). He has published more than 100 peer-reviewed publications and their findings have been published in some important professional journals, such as The Lancet（7 articles）, BMC Bioinformatics，The Lancet Haematology，Plos one and so on.

Dr. Xu specializes in Pathology and Pathophysiology in Oncology. He mainly focuses on the cancer pathogenesis, with a goal of translating mechanistic insights gained for new therapeutic modalities. He published over 110 research papers in prestigious journals, including Mol Cancer (IF=27.401), Nucleic Acids Res (IF=16.971), J Hematol Oncol (IF=17.388), J Thorac Oncol (IF=13.357), Clin Transl Med (IF=11.492), Acta Pharm Sin B (IF=11.413), etc. Presently, Dr. Xu serves as the Associate Editor for BMC Pulm Med, Frontiers in Pharmacology, etc.

Dr. Xin Wang focuses on the roles of B-/T-lymphocytes in tumor development and neurodegeneration. She has published 14 papers in scientific journals including Nature communications, Cancer Research, Cell Discovery, and Journal of Molecular Cell Biology. She also serves as a guest editor or reviewer for more than 9 journals including Nature Aging, Frontiers in series, Biomedicine & Pharmacotherapy, and Journal of Oncology.

Dr. Lufeng Zheng is a collaborative, studious medical oncologist with a strong molecular-biology background, passionate about cancer metastasis, stemness, and drug resistance, and translating research into cancer prevention and control. He has published more than 45 papers in scientific journal including J Hematol Oncol, EBioMedicine, Mol Ther Nucleic Acids, J Med Chem, Genes Dis, Stem Cell Res Ther, Front Immunol, Mol Pharm, FASEB J, etc. He led and contributed to numerous public funded research projects, including the National Natural Science Foundation Project, the Special Postdoctoral Funding Scheme, etc. 

Dr. Bingjie Zhang is currently a postdoctoral fellow in the laboratory of Rahul Satija at the New York Genome Center, where she focuses mainly on developing cutting-edge multimodal single cell technologies to understand epigenetic regulation during cell lineage commitment. As a graduate student under the guidance of Dr. Wei Xie at Tsinghua University, she was dedicated to exploring histone modification reprogramming during early embryo development. She has published several papers as first-author in high impact scientific journals including Nature, Nature Biotechnology, Molecular Cell and Science Advances.

Dr. Yanqing Liu focuses on the roles of p53 in tumor development and functions of non-coding RNA in tumor. He has published more than 20 papers in scientific journals including Cell Death Differentiation, Seminars in Cancer Biology, Molecular Cancer, Protein Cell, and Journal of Molecular Cell Biology. He also serves as reviewer for more than 50 journals including Frontiers in series, BMC series, Molecular Oncology，Biomedicine & Pharmacotherapy, and Cell Communication and Signaling.

Dr. Yanan Ma focuses on how the interaction between innate immune cells (neutrophil and macrophage) and tumor cells affects tumor microenvironment. She has published more than 20 papers in scientific journals including Science Advances, Cell Reports, Nature Cell Biology, PLoS One, Plant Biotechnology Journal, New Phytologist, Molecular Plant, Frontiers in Plant Science, Plant and Cell Physiology, Journal of Experimental Botany, Journal of Integrative Agriculture, Biotechnology and Applied Biochemistry, Plant Science. She also serves as reviewer for more than 11 journals including Journal of Integrative Medicine, Frontiers in Endocrinology, Oxidative Medicine and Cellular Longevity, Frontiers in Genetics, Frontiers in Pharmacology, BMC Cancer, BioMed Research International, Journal of Experimental Botany, Frontiers in Physiology, Frontiers in Molecular Bioscience, Plant Physiology and Biochemistry.

Dr. Zhiwei Fang focuses on biomaterials, gene delivery, and drug delivery. He has authored or co-authored over 17 journal articles including Chemical Reviews, Journal of Nanobiotechnology, Biomaterials Science, and Frontiers in Immunology. He is also a reviewer for many scientific journals.

Dr. Junjie Wu focuses on the initiation, metastasis, and treatment of lung cancers. Until now, his high-level research projects have received fundings from National Natural Science Foundation of China and the Shanghai Postdoctoral Science Foundations. Also, he has published more than 50 papers in scientific journals, including Nature Genetics, Cancer Research and Clinical Cancer Research.

Dr. Jiang is currently a PI and an associate professor at Hangzhou Institute of Technology, Xidian University, Xi’an, China. He earned his Ph.D. in Solid Mechanics from Huazhong University of Science and Technology (HUST), Wuhan, China, in 2018. He then worked as a Postdoctoral Fellow in HUST during 2019-2022. His research interests include design, manufacturing, and application of flexible electronics, bioelectronics, metamaterials, and metasurfaces. He proposed the concepts of ‘flexible metamaterial electronics’ and ‘electronic armor’ in research community for the first time. By now, he has published 1 monograph and more than 20 papers (first author or corresponding author) including some papers in high-profile journals such as Advanced Materials (2 papers), Innovation (2 papers), Materials & Design, Carbon, and Composite Structures. His research proposals have achieved funding support from the National Natural Science Foundation of China, the National Key Research and Development Project, the Fundamental Research Funds for the Central Universities, etc. He served as a grant reviewer for National Natural Science Foundation of China (Engineering and material science). He also served as a guest editor of Rare Metals and a reviewer for 20 SCI journals.

Dr. Jikui Guan focuses on the ALK signaling and ALK-based targeted therapy in neuroblastoma, a childhood cancer arising from the developing sympathetic nerve system. He has published more than 20 papers in scientific journals including Biology of Reproduction, BMC Developmental Biology, Molecular Reproduction and Development, elife, Disease Models & Mechanisms, Science Signaling, CSH Molecular Case Studies, PNAS, EMBO, Journal of Molecular Biology, Cancers and JCO Precision Oncology. He also serves as Review Editor or reviewer for more than 10 journals including Cancer Cell, Cancer Research, Cancer Letters, Cancers, Epigenetics, Biomolecules, International Journal of Molecular Sciences, International Journal of Biological Sciences, Biochemistry and Biophysics Reports, Plos ONE, Molecular Oncology, and Frontiers in Genetics.

Dr. Wanwei Zhang focuses on the function of non-coding RNA in B cell development and the role of retro-transposable elements to genomic instability. He has published many research articles in scientific journals including Nature Genetics, Science Immunology and Molecular Cell. He also serves as reviewer for many journals including Bioinformatics, Frontiers in Genetics, Frontiers in Molecular Biosciences, Journal of Oncology, etc.

Professor Zhu focuses on antitumor drug, biomaterials, drug delivery, functional materials and catalysis. He has authored or co-authored over 85 journal articles and 12 book chapters, including Journal of the American Chemical Society, Angewandte Chemie - International Edition, Coordination chemistry reviews, etc. with more than 3300 citations with a h-index of 32. He is also a reviewer for many scientific journals.

Dr. Gu focuses on the diagnosis and treatment of gastrointestinal cancer and the treatment of Traditional Chinese Medicine. He has published papers in scientific journal including Cochrane Database of Systematic Reviews, Frontiers in Immunology, Oxid Med Cell Longev and etc. He is also Guest editor and reviewer for many scientific journals.

Dr. Yan specializes in Pharmaceutics and Pharmacology. He received the systematic training in anti-cancer treatment at Xiangya Hosital, Central South University, China and Mayo Clinic, USA. Dr. Yan mainly focuses on the cancer therapy, with an ultimate goal of translating mechanistic insights gained for new therapeutic modalities. Yan published about 100 research papers in prestigious journals, including Mol Cancer (IF=27.401), Nucleic Acids Res (IF=16.971), J Hematol Oncol (IF=17.388), J Thorac Oncol (IF=13.357), Acta Pharm Sin B (IF=11.413), etc. Presently, he serves as the Associate Editor for BMC Pulm Med, Frontiers in Pharmacology, etc.

Dr. Bo Li specializes in clinical and basic research on spinal cord injury, bone tumors, and osteoporosis. He has published 34 studies in International Journal of Biological Sciences, J Drug Target, Neuropharmacology, and Neural Regen Res et.al. The H-index is 12 and the cumulative impact factor is 110. He has participated in two Chinese national projects and presided three provincial and municipal projects. He is the editor, guest editor and reviewer of Frontiers in Bioscience-Landmark, Frontiers in Oncology, Frontiers in Immunology and Frontiers in Neuroscience et al.

Dr. Zhenyi Su focuses on regulated cell death and cancer progression; reprogramming innate immunity for cancer therapy; gain-of-function of mutant p53 in cancer metastasis. He has published more than 20 papers in scientific journals including Nature Cell Biology, Cell Death Differentiation, Cell Death & Disease, Molecular Cancer, and EBioMedicine. He also serves as editor or reviewer for more than 20 journals including Frontiers in Pharmacology, Cells, and Journal of Cellular Immunology.

Dr. Zhe Wang focuses on the potential role of PTMs in cancer-related proteins and ferroptosis regulation in response to metabolic stress, especially NRF2-KEAP1 system and splicing proteins. She has published around 10 papers in scientific journals including Molecular Cell, Cancer Research, EMBO Reports, Oncogene and The FASEB Journal. She also serves as reviewer in Oxidative Medicine and Cellular Longevity and Frontiers in Molecular Biosciences.

Dr. Xin Yang focuses on dissecting the role of cancer genetics factors, especially p53, in modulating cancer metabolism and ferroptosis. He has published more than 10 papers in scientific journals including Molecular Cell, Science Advances, Nature Communications, Cancer Research, EMBO Reports, Oncogene and Cell Death Disease. He also serves as reviewer in Frontiers in Oncology and Frontiers in Molecular Biosciences.

Dr. Guohui Sun received his Ph.D. degree from Beijing University of Technology, Beijing, China at July, 2017. Later, he worked as a Postdoctoral Research Associate in the same group for two years. After the Postdoctoral experience, he formally joined Beijing University of Technology as an associate Professor/doctoral Supervisor at August, 2019. His research area focuses on the field of Molecular Toxicology and Applied Pharmacology, including three main aspects: 1) Tumor Pharmacology; 2) Drug Theoretics and Computational toxicology; 3) Cheminformatics in drug discovery and environmental toxicology. He has a good contribution towards the scientific and academic community with numerous research publications in highly prestigious international journals and various presentations in both national and international conferences. He is the senior member of Chinese Pharmaceutical Association, the member of American Chemistry Society, Chinese Chemical Society, Chinese Pharmacological Society and Chinese Society of Biomedical Engineering. He got the 2019/2020 MDPI outstanding reviewer’s representative awards. He is the Editorial board member of Frontiers in Bioscience-Landmark (SCI, IF:3.1); Young Editorial Board Member: Chemical Reagents (Chinese Core Journal); Guest Editor-in-Chief: Molecules (SCI, IF:4.6), Cells (SCI, IF:6.0) and Frontiers in Molecular Biosciences (SCI, IF:5.0).

Dr. Abdelkafi is an Assistant Professor in the laboratory of pathological anatomy and cytology, at Salah Azaiz Institute of Tunisia. He earned his Ph.D. in Cellular and Molecular Bioengineering from University of Science of Tunis (FST), Tunisia, in 2016. Then, He worked as a Postdoctoral Fellow in the laboratory of Biomolecules, Venoms and Theranostic Applications, at Pasteur institute of Tunisia during 2018-2022. His research studies were a part of a highly relevant field for health, at a cutting edge between biochemistry, cell biology and pharmacology towards the development of novel therapeutics tools against cancer and the study of the mechanism of action of antitumor molecules, especially those purified from snake venom. Up till now, he has published 31 research papers in well-known journals.

Dr. Haineng Xu focuses on discovering and developing targeting therapy for ovarian cancers by exploiting genetic vulnerability. He has published over 30 papers in scientific journals including Nature Communications, Cell Reports Medicine, Cancer Research, Molecular Cancer, Cell Death Disease. He served as a reviewer for more than 50 journals including Molecular Cancer, Cancer Letters. He is or has been on the editorial board/guest editor/review editor for BMC Cancer, Open Medicine, Oncology Letters, Frontiers in Oncology, Frontiers in Pharmacology, Frontier in Immunology.  

Dr. Kui Zhang focuses on the initiation, metastasis, and treatment of the malignant cancers. Until now, his high-level research projects have received fundings from National Natural Science Foundation of China and the Chinese Postdoctoral Science Foundations. Also, he has published more than 40 papers in scientific journals including Nature communications, Protein & Cell, Seminars in Cancer Biology, Cell Death & Disease, and Cancer Letters. He also served as the invited reviewers or guest editor for more than 10 journals, including Frontiers in series, Cancers, Cells, Genes & Diseases, Journal of Cell Communication and Signaling, and Toxins.

Dr. Chunjie Jiang focuses on the transcriptional regulation in cancer biology and metabolism. He has published 29 papers in scientific journals including Cell, Science, Nature Neuroscience, and PNAS, including more than 10 first/co-first author papers published on Cell Metabolism, Cell Stem Cell and Genes & Development. He also serves as reviewer for more than 30 journals including Frontiers in series, BMC series, The Innovation, Briefings in Bioinformatics, and Journal for ImmunoTherapy of Cancer.

Dr. Zhiwen Luo served as editorial board/young editorial board member of 21 academic journals and reviewer of more than 30 SCI journals, such as Journal of Advanced Research, Translational Research, Journal of Nanobiotechnology, and so on; published over 30 papers in SCI-indexed journals (27 as (co-)first /corresponding author, total IF>180, 3 articles with IF>15：Small(Cover story), Bioactive Materials, Biomaterials Research, 1 article with IF>10: IJBS); Vice Chairman of the 35th graduate student union of Huashan hospital, Fudan university. He was invited by the official Dingxiang DXY BBS to become a center expert, published nearly 40 popular science articles with over 200,000 visits. 

He is the Principal Research Fellow at University of Southampton. Lai has been long engaged in interdisciplinary research focusing on human mobility, environmental changes, and infectious disease transmission dynamics and early warning. He has more than 130 papers published in scientific journals such as Nature, Science, Lancet Infectious Diseases, Nature Medicine, Nature Human Behaviour, BMJ, and Nature Communications. During the COVID-19 pandemic, he has been leading a series of influential studies for understanding the COVID-19 transmission dynamics and intervention effectiveness, using epidemiological and mobility data obtained from different novel ‘big data’ sources. The findings of these studies have been timely shared with the WHO, Africa CDC, Europe CDC, China CDC, among others, for tailoring COVID-19 intervention strategies, and also featured in main media outlets across the world. His studies on exploring how to use mobile phone data for measuring population mobility, migration and dynamics have aroused great interest, being presented in multiple international conferences including the United Nations 5th conferences International Conference on Big Data for Official Statistics.

He is the Fellow of APS, AVS, IEEE, MRS, HKAES, and HKIE, Chair Professor of Materials Engineering, Department of Physics, Department of Materials Science and Engineering, Department of Biomedical Engineering, City University of Hong Kong. He has authored / co-authored more than 40 book chapters, 2,000 papers in international refereed journals, as well as 1,000 international conference papers including over 150 plenary, keynote, and invited talks, and 15 conference papers received best paper awards. He is a highly cited researcher in materials science from 2016 to 2018, cross-field in 2019 and 2020, materials science in 2021, and cross-field in 2022 according to Web of Science / Clarivate Analytics

Dr Seifedine Kadry has a bachelor’s degree in 1999 from Lebanese University, MS degree in 2002 from Reims University (France) and EPFL (Lausanne), PhD in 2007 from Blaise Pascal University (France), HDR degree in 2017 from Rouen University. He is a Professor of Data Science at Noroff University College, Norway. At present his research focuses on Data Science, education using technology, system prognostics, stochastic systems, and applied mathematics. He is an ABET program evaluator for computing, and ABET program evaluator for Engineering Tech. He is a Fellow of IET, Fellow of IETE, and Fellow of IACSIT. He is a distinguish speaker of IEEE Computer Society.

Dr. Teng Huang graduated from the Nanjing Medical University, and is now working as a physician in the affiliated Hospital of Nanjing University of Chinese Medicine. His research area is focused on studying the the mechanism underlying the role of non-coding RNA molecules in HNSCC radioresistance and metastasis, as well as exploring novel biomarkers for immunotherapies. In recent years, Dr. Huang has published several SCI papers in high impact journals including Journal of Experimental & Clinical Cancer Research, Journal of Translational Medicine, Neoplasma etc. 

 Dr. Yixin Wang is currently a Postdoc at the school of biomedical science, Chinese University of Hong Kong. Dr. Wang has interests in the combined field of RNA therapy, RNA vaccines, COVID-19, and virology are individuals, and fascinated by the potential of RNA molecules to revolutionize disease treatment and prevention. She investigated the virus entry mechanisms of MERS-CoV, viral-host interaction between coronavirus and the host. Since 2019, she has published series of papers related to SARS-CoV-2, successfully reveled the mechanisms of high contagious and immune suppressive of SARS-CoV-2. Related paper was published on the Clinical Infectious Disease and has more than 3000 citations till now.

Ph.D. Roberta works in Auckland University of Technology. She published articles in such journals as Biomedicines, Photodiagnosis and Photodynamic Therapy, BMC Cancerand Cancer Research.

Shihao He is currently a neurosurgeon at Beijing Tiantan Hospital, Capital Medical University. His clinical and preclinical research has focused on cognitive changes and disruption of brain networks in subgroups of patients with moyamoya disease and atherosclerosis. During his postgraduate training, he studied DNA methylation alterations in moyamoya disease, helped understand the involvement of DNA methylation in the pathogenesis of MMD, and proposed novel pathogenic genes as biomarkers. Shihao is currently engaged in the development of moyamoya disease organoid models to explore the molecular mechanisms of pathological angiogenesis and novel therapeutic strategies. Shihao joined the lab of Gary Steinberg, Stanford School of Medicine, in 2022 to conduct visiting research to better understand the pathogenesis of moyamoya disease. He is a member of Science AAAS Students and Postdocs Community. He has published 16 papers in scientific journals, including Journal of Cerebral Blood Flow & Metabolism; Translational Stroke Research; Scientific Reports; BMC Neurology.

The primary emphasis of his research pertains to the involvement of DEAD box RNA helicases in the context of Small Cell Lung Cancers. In addition, he is involved in research pertaining to therapeutic interventions for small cell lung malignancies. He has published several articles in prestigious scientific journals such as the Journal of Molecular Biology, Nucleic Acid Research, Micron, and the Journal of Basic Microbiology. These publications focus on the investigating the regulation of eukaryotic gene expression. In addition, He has received multiple awards, such as the Best Paper award at the 27th Science & Technology Congress by the Government of West Bengal, India, as well as the Best Paper award at the 25th Science & Technology Congress organized by the Government of West Bengal, India. These awards were granted in acknowledgement of his significant contributions to the respective field of study. At now, he is concurrently fulfilling the role of a reviewer for several esteemed scientific journals.

Hamid Heydari Sheikhhossein received his Bachelor's degree in Biology from the University of Mohaghegh Ardabili, Iran, in 2014, and a Master's degree in Nanobiotechnology from the University of Isfahan, Iran, in 2016. After graduation, to further hone his knowledge and skills in Nanobiotechnology, he worked for 15 months as a Research Associate at the Department of Biotechnology at the University of Isfahan. Following a brief stint as a high school teacher at the Ministry of Education, teaching Biology and Sciences in Isfahan, Iran, he moved to Italy in 2022 to pursue his PhD at the Università degli Studi "G. d'Annunzio" Chieti – Pescara, under the guidance of Dr. Natalia Di Pietro and Prof. Adriano Piattelli. His research interests focus on a wide range of applications of nanoparticles and materials in biology and medicine.

Mingdian Tan, a recipient of his PhD from the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences (SIBS), specializes in the field of hepatocellular carcinoma. His research is primarily focused on aspects such as tumor immunity, anti-tumor drug discovery, both in vitro and in vivo testing, as well as the discovery of tumor biomarkers, among other related areas. Dr. Tan's contributions have been featured in notable publications including Cancers, Computational and Structural Biotechnology Journal, and Cell Metabolism. Furthermore, he plays an active role as an executive committee member of the Chinese American Biopharmaceutical Society (CABS). In recognition of his outstanding work, Dr. Tan was awarded the Stanford TRAM award for the years 2021-2023 and has also served as a peer reviewer for more than 20 esteemed scientific journals.

Seyyed Ali Hosseini is a highly accomplished scientist with a strong background in medical imaging, artificial intelligence, and data analysis. Currently, Dr. Hosseini holds the position of Ph.D. Candidate at McGill University, where he is part of the Integrated Program in Neuroscience. Dr. Hosseini serves as an editorial board member and reviewer for esteemed journals such as "Neuroscience-Neurosurgery," "Journal of Psychiatry and Neurochemistry Research," "NeuroImage," and "Computational and Structural Biotechnology." Dr. Hosseini possesses a rich skill set, including expertise in Neuroscience, Radiomics, Genomics, Medical Imaging, Medical Image Processing, Machine Learning (including Keras and PyTorch), and proficiency in programming languages such as Python, MATLAB, and R software.

Dr. Dai focuses on the diagnosis and treatment of brain tumors, especially glioma. He has published more than 80 papers in scientific journal including Biomaterials, Biofabrication, Acta Biomater, ACS Appl Mater Interfaces, Mil Med Res, Wiley Interdiscip Rev Nanomed Nanobiotechnol, Nanoscale, Cell Death Discov, International Journal of Bioprinting, etc. He led and contributed to numerous public funded research projects, including the National Natural Science Foundation project, the Natural Science Foundation of Anhui Province, etc. He was rated as "Excellent Young Physician of Neurosurgery in Anhui Province".

Dr. Aarti Nagayach has published papers in scientific journal including Journal in Chemical Neuroanatomy, PLoS One, Journal of Neuroscience Methods, Brain Research and etc. He is also Guest editor and reviewer for many scientific journals including Journal of Clinical Medicine，BioMedicine，Journal of Clinical Medicine and so on. She has attended more than 10 conferences and  presentations.

Prof. Chen is currently an associate Professor at the Translational Medicine Research Center of Guizhou Medical University and a postdoctoral fellow at the affiliated hospital of Guizhou Medical University. Her research focuses on the inflammatory microenvironment and tumor chemotherapy resistance. In recent years, Prof. Chen has published over 20 SCI papers in highly influential journals such as Chemical Science, Cell Death Disease, BBA - Molecular Basis of Disease, and Cancer Gene Therapy. Prof.Chen presides over a project funded by the National Natural Science Foundation of China

Dr. Ahmad Reza Farmani focus on Tissue Engineering, Bone Tissue Engineering, Bioceramics, Biomaterial Science, Biomaterials in Cancer Treatment Research, Nanobiomaterials, Tumor Treating Fields, Pulsed Electric Field, Bioelectromagnetic, Blood derivated biomaterials, Nanobiocomposite, and Bioengineering based on Biophysical Stem Cell Stimulation. His intellectual basis is to use the engineering perspective to build new materials for new applications in medical engineering, regenerative medicine, and cancer treatment. Currently, He is an assistant professor in the Department of Tissue Engineering at Fasa University of Medical Sciences, Iran. He presented more than 24 papers at 12 national and international conferences. He won the Best Poster Award at the 6th International Congress of Wound and Tissue Repair (WTRC-2022). Also, he published more than 12 research and review papers in national and international journals. Amongst, one of his articles was selected as Top Downloaded Article, among works published in an issue between 1 January 2021 – 31 December 2021, in the American Journal of Reproductive Immunology.

Dr. Rose's research interest is aimed at obtaining new compounds from medicinal plants which could provide leads for the treatment of inflammatory diseases and cancer. Okiemute Rosa Johnson-Ajinwo obtained her BSc in Pure and Industrial Chemistry from the Nnamdi Azikiwe University, Awka, Anambra state, Nigeria in 1998 and proceeded to the University of Port Harcourt in 2000, for a Master’s degree in Analytical Chemistry.  By 2006, she joined the Department of Pharmaceutical/Medicinal Chemistry of the Faculty of Pharmaceutical Sciences in the University of Port Harcourt as a Lecturer 11. Currently, she is an Associate Professor and the Acting Head of Department in the Department of Pharmaceutical/Medicinal Chemistry of the Faculty of Pharmaceutical Sciences at the University of Port Harcourt, Rivers State, Nigeria, where she has lectured for close to 17 years. She has published more than 25 papers in reputable journals, supervised over 15 undergraduate projects and 2 post-graduate research works.